EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma

2026-525808-94-00 · tracked via the Priya Life Science EU tracker

Sponsor

Region Hovedstaden

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Neoplasms

Decision date

10/07/2026

Enrollment target

Sites

Denmark

Condition studied

Oncology

Investigational medicinal product(s)

LP-184

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Phase Ib: Dose-Limiting Toxicity (DLT) according to CTCAE version 5.0., Phase Ib: Recommended Phase 2 Dose (RP2D)., Phase ll: Objective Response Rate (ORR) according to RECIST criteria version 1.1.

Endpoint detail

Progression-Free Survival (PFS), Overall Survival (OS), Duration of Response (DoR)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525808-94-00 on CTIS ↗ ← All trials in the EU